Skip to content

A clinical study of Chinese herbal compound TJAOA101 and TJAOA102 in protecting of ovarian aging

The role of TJAOA101 and TJAOA102 Chinese herbal compound in protecting ovarian aging: a prospective and before-after study.

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055539
Enrollment
Unknown
Registered
2022-01-11
Start date
2021-09-30
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian aging

Interventions

Group 1:TJAOA Chinese herbal compound 101
Group 2:TJAOA Chinese herbal compound 102

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 55 years; 2. The diagnosis of women is one of DOR, POI, early menopause or menopausal syndrome and wish to improve ovarian function or menopausal syndrome; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. The patient is known to be allergic to or unsuitable to the Chinese herbal compound; 2. Women who are pregnant and lactating; 3. Patients with POI or DOR had been in menopause for more than 1 year; 4. Abnormal uterine bleeding, except for ovulation disorders; 5. Women who are taking hormone drugs and have stopped taking them within 3 months; 6. The diagnosis of women is endometriosis, myadenosis, submucosal fibroids or the size of non-submucosal fibroids is greater than 4 cm; 7. The nature of pelvic mass is unknown; 8. The diagnosis of women is polycystic ovary syndrome, hyperprolactinemia, hyperandrogenemia, diabetes, thyroid, and adrenal dysfunction, and other endocrine diseases affecting ovulation; 9. Complicated with serious primary diseases such as cardiovascular, liver, kidney, lung, biliary, hematopoietic system (Hb<90g/L) and malignant tumor, and psychiatric patients; 10. Patients who are participating in other clinical trials or have participated in other clinical trials within the last month; 11. Patients who are unsuitable for the study evaluated by the investigator.

Design outcomes

Primary

MeasureTime frame
Sex hormone;AMH, Anti-millerian hormone;Menstruation recovery rate;AFC, Number of antral follicles;Patient’s life quality;

Secondary

MeasureTime frame
Safety assessment;

Countries

China

Contacts

Public ContactWang Shixuan

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

shixuanwang@tjh.tjmu.edu.cn+86 27 83663180

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026